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Background: Beside neurofibrillary tangles, amyloid plaques are the major histological hallmarks of Alzheimer’s
disease (AD) being composed of aggregated fibrils of β-amyloid (Aβ). During the underlying fibrillogenic pathway,
starting from a surplus of soluble Aβ and leading to mature fibrils, multiple conformations of this peptide appear,
including oligomers of various shapes and sizes. To further investigate the fibrillization of β-amyloid and to have
tools at hand to monitor the distribution of aggregates in the brain or even act as disease modulators, it is essential
to develop highly sensitive antibodies that can discriminate between diverse aggregates of Aβ.
Results: Here we report the generation and characterization of a variety of amyloid-β specific human and human-like
antibodies. Distinct fractions of monomers and oligomers of various sizes were separated by size exclusion
chromatography (SEC) from Aβ42 peptides. These antigens were used for the generation of two Aβ42 specific
immune scFv phage display libraries from macaque (Macaca fascicularis). Screening of these libraries as well
as two naïve human phage display libraries resulted in multiple unique binders specific for amyloid-β. Three
of the obtained antibodies target the N-terminal part of Aβ42 although with varying epitopes, while another
scFv binds to the α-helical central region of the peptide. The affinities of the antibodies to various Aβ42
aggregates as well as their ability to interfere with fibril formation and disaggregation of preformed fibrils
were determined. Most significantly, one of the scFv is fibril-specific and can discriminate between two
different fibril forms resulting from variations in the acidity of the milieu during fibrillogenesis.
Conclusion: We demonstrated that the approach of animal immunization and subsequent phage display
based antibody selection is applicable to generate highly specific anti β-amyloid scFvs that are capable of
accurately discriminating between minute conformational differences.
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Alzheimer’s Disease is a slowly progressing, irreversible
neurodegenerative disorder and the most prevalent cause
of dementia in the elderly. With 7.7 million new cases
every year and a survival time after diagnose of 7.1 years
[1] the number of over 35 million people suffering as of
2012 is thought to be tripled by the year 2050 according
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creativecommons.org/publicdomain/zero/1.0/by this, the annual cost generated by dementia, currently
exceeding 600 billion $, will most likely rise to more than
1,100 billion $ within the next 15 years. It is the socioeco-
nomic impact which lays the foundation for the urgent
need of diagnostic and therapeutic tools in AD that target
the disease and its progression at an early stage.
Histological hallmarks of AD are neurofibrillary tan-
gles, comprised of hyperphosphorylated tau protein [2,3],
and amyloid plaques that are composed of aggregated
amyloid-β peptides [4-6]. Amyloid-β is regarded as the
main culprit causing the neuropathology in AD and is re-
leased from the amyloid precursor protein by sequential
cleavage with β- and γ-secretases. This processing results
in peptides of various amino acids (aa) in length with the
majority being 40 aa (90%) and 42 aa (10%) long [7], henceticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Aβ lead to an imbalance between elevated peptide produc-
tion and decreased clearance from the brain, shifting the
concentration and facilitating self aggregation of β-
amyloid. Once a critical concentration is surpassed, the ag-
gregation follows a nucleation-dependent polymerization
process to form mature fibrils with various oligomeric in-
termediates along the way [8,9]. A multitude of diverse Aβ
aggregates has been identified, such as dimers [10,11], het-
eromorphous oligomers [12-16], or protofibrils [17], that
represent the last stage before the final transition into the
fibril forms. Oligomers and protofibrils are widely
regarded as the main toxic species in AD although the
exact nature of the toxic entity - if such a form even exists
[18] - has yet to be elucidated [19-25].
While on the one side researchers investigating how Aβ
contributes its toxicity to AD there are still other prob-
lems close at hand: up until today it is neither possible to
diagnose the disease at an early, presymptomatic stage nor
to treat patients beyond symptomatic relief, e.g. alleviating
behavioral problems. The first symptoms emerge decades
after neuronal changes occur [26]. Therefore the current
diagnoses target progressed characteristics of the disease
and are composed of various imaging methods such as
x-ray computed tomography (CT) succeeded by magnetic
resonance imaging (MRI) [27,28] or positron emission tom-
ography (PET) [29], additional to cognitive tests and the
assessment of the patient’s history regarding the worsen-
ing of cognition. Still, the combination of these tools does
not result in an absolute accuracy of the diagnosis [30].
Additionally, to modify the progression of Alzheimer’s
disease it is essential to apply potential therapies at an
early stage, long before amyloid plaques are formed [31].
Current treatment of AD involves acetylcholinesterase in-
hibitors (e.g. Donepezil) [32,33] and N-methyl-D-aspartate
(NMDA) antagonists [34] to improve cognitive functional-
ity, up until now only with remote success. For an early
and accurate diagnosis of the disease as well as for a better
treatment hypothesis, it is essential to get a deeper insight
on the aggregation of amyloid-β.
During the transition from Aβ monomer to fibrils, dif-
ferent conformational epitopes are expected to form,
which may be used to differentiate between diverse ag-
gregation forms of Aβ using antibodies specifically rec-
ognizing these conformational epitopes. Phage display
and immune libraries from macaque have been proven
in the past to be an effective instrument for the gener-
ation of conformation specific antibodies, already pro-
viding a source of binders against targets like ricin [35],
anthrax [36,37], bacterial surface proteins such as Crf2
from Aspergillus fumigatus [38], the Venezuelan equine
encephalitis virus (VEEV) [39] and the western equine
encephalitis virus (WEEV) [40] or botulinum neurotoxin
A [41]. A further distinct advantage of NHP (non humanprimate) derived immune libraries is the very high de-
gree of identity of the antibodies to human antibodies
[42] allowing for very easy transition of the scFvs from
diagnostic to therapeutic tools. Phage display antibody
generation further allows to control the conditions and
conformations during the very moment of binder selec-
tion, offering additional chances to steer antibody speci-
ficity towards conformational epitopes [43].
Results
Antigen preparation (Aβ42)
Fractions of Aβ42 monomers, protofibrils and mature fi-
brils were prepared from synthetic Aβ42 peptide to serve
as antigens. Depending on the purification method, the
separation via SEC with one column resulted either solely
in pure monomers (Figure 1A) or a monomer fraction and
a second peak representing a heterogeneous mixture of
different sized oligomers, namely protofibrils (Figure 1B).
These protofibrils range between 15 kDa and 500 kDa and
display various forms and morphologies, with diameters of
8–10 nm and a length of up to 200 nm. Protofibrils were
further separated by two SEC columns connected in series
to obtain smaller or larger oligomers (Figure 1C). Earlier
eluting fractions include filaments significantly larger
than 200 nm (LO = large oligomers) while later eluting
fractions consist predominantly of short fibrils (MO=
medium oligomers) of up to 100 nm and small, circular
aggregates (SO = small oligomers) that can be smaller than
10 nm. Mature fibrils are generated from monomers by
incubation at 37°C for 24 h and 300 rpm. We observed
the same distribution of aggregates among the fractions
with two different running buffers: 10 mM Tris–HCl,
pH 7.4 or 100 mM Na-Borate, pH 8.6. These running
buffers were chosen depending on the later purpose of the
antigen. Aβ42 in 10 mM Tris buffer cannot be used for
amine coupling of the antigen (e.g. in SPR experiments)
while Aβ42 in 10 mM Tris–HCl, pH 7.4 is more suitable
for immunization.
Immunization and antibody phage display library
construction
Late fractions of SEC purified Aβ42 oligomers (SO) were
used for the immunization as well as for measuring the
immune response by enzyme linked immunosorbent assay
(ELISA). Ten days after the fifth boost, the antibody titer
was determined to be 1 per 80,000. Nine weeks later a
sixth boost was administered. PCR products of antibody
genes were collected six and nine days after the last boost.
The DNA fragments were pooled and subcloned into
pGemT, resulting in a total of 2.7*106 and 4.4*105 individ-
ual clones for VH and VL respectively. pHAL35, a modi-
fied version of the pHAL14 phage display vector, was used
for phage display library construction by two consecutive











Figure 1 Generation of Aβ42 fractions. Aβ42 peptide was solubilized in 6 M Guanidin-HCl (for sole monomer preparation) or by DMSO, dH2O
and Tris (for protofibril preparation) and purified by SEC. (A) single column purification of a sole monomer (M) fraction. Fibrils (F) were derived
from monomers by incubation at 37°C, (B) single column purification of a monomer (M) and protofibrils (PF) fraction, (C) purification via two
columns connected in series to further separate the protofibrils fraction and obtain large oligomers (LO), medium oligomers (MO) or small
oligomers (SO). Left: SEC chromatograms, right: representative TEM images, scale bar corresponds to 200 nm.
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MluI and NotI followed by cloning of the VH gene frag-
ments via SfiI and HindIII. The final libraries comprised a
total of 2.9*107 individual clones. The insert rates were de-
termined by colony-PCR to be 60% for the kappa library
and 80% for the lambda library. Both libraries were pack-
aged using M13K07 as helperphage.
Isolation of Amyloid-β specific scFvs
Multi-step pannings, with or without competition with
unwanted forms of Aβ42 antigen (e.g. panning on immo-
bilized fibrils with soluble monomers added for competi-
tion), were carried out to generate antibodies with diverse
specificities against Amyloid-β. In addition to the twomacaque IgG derived immune phage display libraries, two
IgM derived naïve human phage display libraries HAL7/8
[44] were employed. From a total of 54 pannings, 6088
antibody clones were analyzed by ELISA and 612 hits
were identified. Eight unique monoclonal antibodies with
individual sequences, named PaD97-D6 from the naïve
human libraries and PaD172-F8, PaD172-F12, PaD213-
A5, PaD218-E6, PaD233-E5, PaD235-D2 and PaD236-H2
from the immune libraries were selected (Table 1) based
on their specificity, their above average absorption or
because of their high signal to noise ratio in the screen-
ing ELISAs. All eight antibodies were produced as scFvs
and scFv-Fc fusions (Yumabs) [45] in mammalian cell cul-
ture. PaD172-F8, PaD218-E6 and PaD235-D2 could not
Table 1 Antibody pannings
Libraries
HAL7/8 Aβ libraries (λ + K) Total
Number of pannings 28 26 54
Clones investigated 3236 2852 6088
Hits 2 610 612
Unique binders 1 7 8
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experiments.
Yumabs consist of a human IgG1 Fc part that is linked
with two scFvs instead of Fab-fragments.
The specificity of PaD97-D6, PaD172-F12, PaD213-A5,
PaD233-E5 and PaD236-H2 was initially verified on dif-
ferent forms of Aβ42, i.e. monomers, small, medium and
large oligomers and mature fibrils by ELISA (Figure 2).
Here, all antibodies except PaD213-A5 showed no pre-
dominant binding to any distinct form. Only PaD213-A5
exhibited specificity towards Aβ42 fibrils. Additionally,
binding to fibrils of other amyloidogenic peptides was
evaluated in the same manner. These peptides included
mature fibrils of Aβ40, α-synuclein, Huntingtin (Htt
(aa105-138)) and fibrils of Tau (isoform F), the K18 do-
main and the PHF6 domain of Tau. PaD97-D6 exhibited
some cross reactivity with Tau fibrils of the isoform F
(data not shown).
PaD213-A5 differentiates between various Aβ42 fibrils
Aβ42 peptide was purified in two different running
buffers, 10 mM Tris–HCl, pH 7.4 or 100 mM Na-Borate,
pH 8.6, depending on its later application. Repeated
immunological assays elucidated the selectivity of PaD213-
A5 towards a distinct form of Aβ42 fibrils. This anti-
body exhibited no affinity to mature fibrils produced in
Tris–HCl buffer while on the other hand binding to fibrils
generated in Na-Borate buffer (Figure 3A). TEM investi-
gation revealed major differences in the composition of
the fibrils. Na-Borate derived fibrils exhibited a compact
bundle of 4–8 individual fibrils twisted helically every
130–150 nm (Figure 3B) while Tris derived fibrils con-
sisted of one discrete fibril with a helical twist around its
axis about every 50 nm (Figure 3C).
All antibodies detect different epitopes
The determination of the epitope of the Amyloid-β spe-
cific antibodies was performed using a peptide spot
membrane (Figure 4). Each spot on the membrane con-
sisted of 15 AA of the Aβ42 peptide with an offset of 1
AA. Epitope mapping was performed with all antibodies
to verify binding to linear epitopes. No binding was de-
tected with PaD213-A5 since it is fibril specific, i.e. detect-
ing a conformational epitope. PaD97-D6, PaD172-F12
and PaD236-H2 bound to the N-terminus of Aβ42albeit differing in the exact epitope with position 1 to 13
for PaD97-D6 (“DAEFRHDSGYEVH”), position 4 to 13
for PaD172-F12 (“FRHDSGYEVH”) and position 5 to 13
for PaD236-H2 (“RHDSGYEVH”). A more precise deter-
mination of the epitopes for these three antibodies was
impeded by the spot sizes of 15 AA in length. PaD233-E5
bound to the central region of Aβ42. Here, the exact epi-
tope was more narrowly determined by amino acids 17 to
22 (“LVFFAE”) (Figure 5).
Affinity determination of the scFvs by surface plasmon
resonance (SPR)
Affinity determination was carried out on various Amyloid-
β monomers, protofibrils and fibrils, via BIAcore™ with dif-
ferent antibody concentrations and resulted in KD values in
the micro- to nanomolar range (Table 2). The antibodies
targeting the aminoterminal end of Aβ42 and each anti-
body, PaD97-D6, PaD172-F12 and PaD236-H2, exhibited
similar affinities towards all three forms of antigen. In con-
trast, PaD233-E5 which binds to the core region of Aβ42
shows an 100-fold elevated affinity to Aβ42 monomers,
with a KD of 10 nM, when compared to protofibrils and fi-
brils. PaD213-A5 bound solely to Aβ42 fibrils with a KD of
36 μM.
Yumabs inhibit Aβ42 fibrillogenesis in a concentration
dependent manner
When binding to Aβ42 monomers, an inhibitory effect
of the antibodies on fibril formation could be possible.
We tested the effect of all antibodies on the formation of
mature Aβ42 fibrils from pure monomers by visualizing
potential fibrils using transmission electron microscopy
(TEM) and measuring Thioflavin T (ThT) fluorescence.
ThT is a dye that, upon binding to amyloid fibrils, exhibits
fluorescence. Thus it allows for the assessment of fibril
formation, which was investigated in this study by com-
bining part of the sample with ThT stock solution every
six hours during the first 24 h, every 12 h during the next
24 h and with a final checkpoint after 96 h (Figure 6).
Bivalent scFv-Fc antibodies (Yumabs) were able to inter-
fere with fibril formation at a substoichiometric level for
PaD97-D6, PaD233-E5 and PaD236-H2 (Figure 6). The
influence is most notable for PaD233-E5, the antibody tar-
geting the central α-helical region of Aβ42. Addition of
4 μM scFv-Fc antibody to 5 μM Aβ42 monomers resulted
in a reduction in ThT fluorescence of about 25% for
PaD97-D6, nearly 50% for PaD236-H2 and even more ele-
vated forPaD233-E5 after 96 h of incubation (Figure 6).
Comparison with PaD213-A5 or the negative control
scFv-Fc antibody indicates that this effect is not contrib-
uted to antibody concentration or design. Interestingly,
PaD172-F12, also directed against the N-terminal end of
Aβ42 like PaD97-D6 and PaD236-H2, did not show an in-
hibitory effect.
Figure 2 Specificity determination of scFv-Fc antibodies on 100 ng of Aβ42 monomers (yellow), small oligomers (blue), medium oligomers (green),
large oligomers (red), fibrils (black) or BSA (dotted black). Dilutions of scFv-Fc antibodies were applied and detected using a peroxidase-labeled goat
anti-human antibody recognizing the Fc fragment (1:35,000).
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fibrils by antibody addition, was evaluated by ThT reading
and TEM analysis as well. No antibody mediated disinte-
gration of mature fibrils (data not shown).
Discussion
Aβ42 oligomers were chosen for the immunization of
the NHP due to their reported elevated toxicity, making
them a potential target for immunotherapy. Using theimmune libraries and two previously established human
naïve libraries [32] in a multistep panning, we created nu-
merous antibody fragments specific for β-amyloid with an
interesting spectrum of different binding properties.
The initial validation utilizing titration ELISAs demon-
strated antibody specificity towards either form of Aβ42
aggregates but no predominant preference for PaD97-D6,
PaD172-F12, PaD233-E5 or PaD236-H2. Epitope mapping
further revealed that three of these four antibodies detect
AB C
Figure 3 PaD213-A5 discriminates between different Aβ42 fibrils. A, titration ELISA of PaD213-A5 on different kinds of Aβ42 fibrils. Plates were
coated with 100 ng of Aβ42 fibrils from 100 mM Na-Borate, pH 8.6 (solid line) or 10 mM Tris–HCl, pH 7.4 (dotted line). Bound ScFv-Fc antibodies
were detected using a peroxidase-labeled goat anti-human antibody recognizing the Fc fragment (1:35,000). Right: representative TEM images of
Aβ42 fibrils obtained from monomers purified in (B) 100 mM Na-Borate, pH 8.6 or (C) 10 mM Tris–HCl, pH 7.4, the scale bar corresponds
to 200 nm.
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the central region. This is consistent with previous find-
ings that the amino-terminal region of Aβ42 is immuno-
dominant in human [46], NHP [47] as well as in dog
[48], mouse [49] and rabbit [50] explaining the quantity
of antibodies and antibody fragments directed against
this part of the peptide in this work and previous stud-
ies [49,51-55], with Bapineuzumab being the most prom-
inent one. Solely PaD213-A5 demonstrated a high
selectivity towards Aβ42 fibrils and did not bind to any
other form of Aβ42. Remarkably, PaD213-A5 was able to
even discriminate between two different Aβ42 fibril prepa-
rations, depending whether the amyloid-β peptide was
purified in 10 mM Tris–HCl/pH 7.4 or in 100 mM Na-
Borate/pH 8.6.
Meinhardt et al. [56] already described other prepar-
ation dependent polymorphisms in Aβ40 fibrils. Based
on their findings, it seems likely that the difference in
the acidity of the buffers contributes to a morphological
change in the fibril structure, a hypothesis that is sup-
ported by our TEM analysis. It can be hypothesized thatPaD213-A5 distinguishes between both types of fibrils
through the detection of a conformational epitope which
may well be dependent on the helical twist angle or the
interspace distances between two single strands that make
up the mature β-amyloid fibril. While there are antibodies
and polyclonal sera that are fibril specific [57-59] the spe-
cificity observed here was not reported for any other
known antibody. It remains to evaluated whether these
structural differences have any significance in vivo.
To investigate the antibodies for a potential application
as disease modulators, we assessed their impact on the
fibrillization of Aβ42 monomers in vitro. The fibrillogen-
esis of Aβ42 is a nucleation-dependent polymerization
process [8]. When a certain concentration threshold of
monomers is surpassed small aggregates termed “nuclei”
accrue and polymerization starts. These nuclei are elon-
gated by addition of monomers forming larger aggregates
and ultimately fibrils. It has been previously shown that
antibodies targeting the N-terminal end of amyloid-β ex-
hibit an inhibitory effect on the fibrillogenesis [60-63]. With
the majority of our antibodies recognizing Aβ42 monomers
Figure 4 Epitope mapping analysis. Left: Membranes covering the complete sequence of Aβ42 with peptides of 15 amino acids in length and an
offset of 1 amino acid. 10 μg/mL of scFv-Fc antibodies were used for staining, antibodies were detected using a peroxidase-labeled goat anti-human
antibody recognizing the Fc fragment (1:70,000) PaD213-A5 not shown (no signal seen anywhere). Right: peptide spot map.
Droste et al. BMC Biotechnology  (2015) 15:57 Page 7 of 13this gives rise to the idea that they can intervene in the ini-
tial aggregation by preventing interactions of β-amyloid
peptides thus retarding or even inhibiting fibril formation
[64].
PaD97-D6 and PaD236-H2 demonstrate a concentra-
tion dependent retardation of fibril formation resulting
in shorter fibrils and an overall stronger appearance of
unstructured aggregates. They do not prevent fibrilliza-
tion entirely, which suggests a steric hindrance during
monomer-monomer attachment [61]. Albeit also binding
to the amino-terminal region of Aβ42, PaD172-F12 ex-
hibited no substantial effect on fibril formation. With no
major discrepancies in the affinity compared to PaD97-D6
or PaD236-H2, this result is likely to be accounted to
the minute differences in epitopes. It is plausible that
PaD172-F12 attaches to monomers in such way that no
steric hindrance is administered towards the core region
of Aβ42. A partial masking of that area by an antibody
would minimize monomer-monomer interaction and im-
pede fibril formation. Epitope mapping demonstrates that
PaD97-D6 binds Aβ1–13 while PaD172-F12 and PaD236-H2
bound further downstream (Aβ4–13 for PaD172-F12 and
Aβ5–13 for PaD236-H2). Obviously, PaD97-D6, PaD172-F12
and PaD236-H2 attach to the monomer with different
spatial arrangements. Further, the region of the epitope
on the Aβ42 peptide may contribute to the similar KDvalues to different aggregates measured for these anti-
bodies. PaD97-D6, PaD172-F12 and PaD236-H2 bind to
the amino-terminal end of the β-amyloid peptide, an epi-
tope that is exposed in monomers and aggregates during
fibrillogenesis [54]. This may allow nearly equal affinities
of the before mentioned antibodies to all three forms.
PaD233-E5 impacts fibril formation, which is not sur-
prising as it targets the central region of Aβ42 with
Aβ17–22 (LVFFAE), a part of the hydrophobic core elem-
ent (LVFF) that is essential for β-sheet formation during
fibrillization [65]. Together with the elevated affinity to-
wards Aβ42 monomers, this effect can be accounted to two
probable modes of action or a mixture of both. PaD233-E5
either masks the LVFF-motif thus directly preventing
monomer-monomer interaction. This effect was postu-
lated by Legleiter et al. for the antibody m266, the murine
progenitor of Solanezumab [61]. m266 targets the same
epitope as PaD233-E5, binding to Aβ16–24 (KLFFAEDV)
[66] and prevents the formation of fibrils and even proto-
fibrils. The other possible explanation is the attachment of
PaD233-E5 to Aβ42 monomers thus shifting the concen-
tration threshold of soluble β-amyloid beneath the critical
limit necessary for the polymerization process. Interest-
ingly, PaD233-E5 has a much more pronounced influence
on amyloid-β fibrillogenesis than any other antibody as
visualized by TEM. Yet the ThT absorbance after 96 h is
Figure 5 Visualization of the epitopes on Aβ42 on PDB structure 1z0q (Aβ42 monomer in aqueous solution, [78]). Left, right: same molecule
rotated by 180° horizontally. Areas of the potential epitopes for (A) PaD97-D6, (B) PaD172-F12, (C) PaD233-E5 and (D) PaD236-H2 are colored
green, the first amino acid of each epitope is colored red to facilitate recognition.
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tion for the formation of smaller aggregates with a β-sheet
rich content. This would suggest the latter mode of action
described for PaD233-E5 to be more dominant in the in-
hibition process.
The impact on AD immunotherapy of the antibodies
presented in this work has to be further validated. Re-
cently, Bapineuzumab (directed against the N-terminus of
Aβ) and Solanezumab (directed against the central regionTable 2 Affinity determination by SPR
KD [M] on Aβ42 antigen
Antibody Monomers (X2) Protofibrils (X2) Fibrils (X2)
PaD97-D6 2.3 × 10−6 (4.9%) 4.2 × 10−6 (2.4%) 9.1 × 10−7 (2.3%)
PaD172-F12 9.4 × 10−7 (2.4%) 1.5 × 10−6 (1.7%) 9.2 × 10−7 (2.4%)
PaD213-A5 No binding No binding 3.7 × 10−6 (1.1%)
PaD233-E5 1.0 × 10−8 (6.6%) 3.6 × 10−6 (1.4%) 1.2 × 10−6 (1.4%)
PaD236-H2 3.5 × 10−7 (2.5%) 5.8 × 10−7 (1.9%) 6.2 × 10−7 (5.7%)
Chi2 (Χ2) values are indicated in brackets.of Aβ), both not conformation specific antibodies, failed
to meet the expected endpoints in clinical phase 3 stud-
ies albeit having shown positive results in preceding
studies (reviewed in [67]). The results of the initial
characterization for the Yumabs in this work are promis-
ing. Especially PaD213-A5 exhibits a highly interesting
property of differentiating between Aβ42 fibrils based on
their conformation that is not yet described in literature
and its implication on AD diagnosis and therapy has to be
further validated with in vivo data.
Conclusion
Among the investigated antibody fragments we found
three scFvs exhibiting a general specificity towards β-
amyloid while two scFvs, PaD213-A5 and PaD233-E5,
presented a tendency to better bind to certain forms of
Aβ42. PaD213-A5 is highly specific for mature Aβ42
fibrils and identified a novel structural variation in fibril-
lar structures. PaD233-E5, albeit binding also oligomers
and fibrils, showed a 100fold increased affinity towards
Figure 6 Influence of scFv-Fc antibodies (Yumabs) on Aβ42
fibrillogenesis. Left: 5 μM Aβ42 monomers were incubated with
2 μM (red), 1 μM (blue), 0.5 μM (green) or 0 μM (black) of scFv-Fc
antibodies at 37°C under constant agitation of 300 rpm, ThT
fluorescence was monitored over a time course of 96 h. All
measurements were carried out in triplicates, the error bars represent
the respective standard deviation. Right: representative TEM images
of the fibrils formed from of 5 μM Aβ42 monomer after 96 h
incubation in the presence of 2 μM scFv-Fc antibody, scale bar
corresponds to 400 nm.
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ing an inhibitory effect on the fibrillization of Aβ42
monomers.
While the in vivo relevance of these differences is still
to be established, the study confirms that the approach
of animal immunization and subsequent phage display
based antibody selection is applicable to generate highly
specific anti β-amyloid scFvs that are capable of accurately
discriminating between minute conformational differences.
Methods
Antigen preparation
Aβ42 peptides were synthesized by Dr. James I. Elliott at
Yale University (New Haven) [68]. All Aβ42 antigens, in-
cluding monomers, protofibrils and different size oligo-
mers derived thereof by further fractionation as well as
Fibrils were prepared according to [18,69].
TEM sample grid preparation and image acquisition
5–10 μL of sample was deposited on a formvar coated
200 mesh TEM grid (EM Science, Hatfield) and incubated
for 1 min. Excess fluids were wicked away with a piece of
filter paper. The grid was washed twice by applying 10 μL
of dH2O before incubating the sample twice with 10 μL of
2% (w/v) uranyl acetate for 1 minute each. The grid was
dried with a vacuum pump, incubated for 5 min at room
temperature to completely dry off and stored in the de-
signed container. Imaging was carried out on a Tecnai G2
Spirit microscope at an acceleration voltage of 80 kV.
Ethics statement and animal care
All animal studies presented were given specific approval
from the Institut de Recherche Biomédicale des Armées
ethics committee (Comité d'éthique de l'Institut de
Recherche Biomédicale du Service de Santé des Armées)
under authorization no. 2008/03.0 and were performed
in accordance with all relevant French laws and ethical
guidelines, including, in particular (i) “partie règlemen-
taire du livre II du code rural (Titre I, chapitre IV, sec-
tion 5, sous-section 3: expérimentation sur l’animal)”,
(ii) “décret 87–848 du 19-10/1987 relatif aux expéri-
ences pratiquées sur les animaux vertébrés modifié par
le décret 2001/464 du 29/05/2001”, (iii) “arrêté du 29
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animale pour le Ministère de la Défense” and (iv) “in-
struction 844/DEF/DCSSA/AST/VET du 9 avril 1991
relative aux conditions de réalisation de l’expérimen-
tation animale”.
Animal care procedures complied with the regulations
detailed under the Animal Welfare Act [70] and in the
Guide for the Care and Use of Laboratory Animals [71].
Animals were kept at a constant temperature (22°C+/−2°C)
and relative humidity (50%), with 12 hours of artificial light
per day. They were housed in individual cages (6 per room),
each of which contained a perch. Animals were fed twice
daily, once with dried food and once with fresh fruits and
vegetables, and water was provided at the same time. Food
intake and general behavior were observed by animal
technicians during feeding times, and veterinary surgeons
were available for consultation if necessary. Veterinary
surgeons also carried out systematic visits to each NHP-
room twice weekly. The environmental enrichment pro-
gram for the nonhuman primates was limited to games
with animal care staff and access to approved toys. The
well-being of the animals was monitored by the attending
veterinary surgeon. Animals were anesthetized before the
collection of blood or bone marrow by an intramuscular
injection of 10 mg/kg ketamine (Imalgene®, Merial, Lyon,
France). Analgesics were subsequently administered, through
a single intramuscular injection of 5 mg/kg flunixine
(Finadyne®, Schering Plough, Courbevoie, France) in the
days after interventions if the animal technicians sus-
pected that the animal was in pain, on the basis of their
observations of animal behavior. None of the nonhuman
primates were killed during this study.
Animal immunization
A male macaque (Macaca fascicularis) was immunized
with a total of 6 subcutaneous injections of purified and
sterile filtered small oligomers of Aβ42. Injections were
carried out with 50 μg antigen (inj. 1–3) and 50 μg antigen
(inj. 4–6) at a one month interval, except for the sixth in-
jection which was given 2 months after the fifth.
Construction of the anti Aβ42 scFv phage display
library
Six and nine days respectively after the last boost, RNA
was isolated using Tri Reagent (Molecular Research
Center Inc, Cincinnati, USA) from the bone marrow of
the immunized macaque and transferred into cDNA by
reverse transcription. DNA was amplified by PCR using
seven different oligonucleotide primers for the coding re-
gions of the light chain and nine different primers for the
heavy chain [72]. After amplification, PCR products were
pooled and subcloned into pGemT (Promega, Madison,
Wisconsin). Antibody inserts in pGemT were re-amplified
with individual primer sets for the kappa (κ) and lambda(λ) sublibraries introducing specific restriction sites for the
cloning of the final library as described [44]. Library pack-
aging was carried out using M13K07 as helperphage.Selection of recombinant antibodies against Aβ42
ScFvs were isolated in vitro by panning the macaque
derived immune libraries as well as the human naïve li-
braries HAL7/8 [44] as described previously [73]. Antigen
coating was carried out at 4°C overnight in 100 mM
Na-Borate buffer and constant amounts (1 μg) of antigen
were used as bait during the three panning rounds. To in-
crease the possibility of obtaining antibodies specific for
one Aβ42 conformation, competition with unwanted con-
formations of Aβ42 was done using 3 μg of antigen or
5 μg for Aβ42 fibrils respectively. Individual colonies of
bacteria infected with eluted antibody phage were isolated
and inoculated in MTP (microtiter plate) wells to produce
soluble antibody fragments as described previously [74].
The produced scFvs were analyzed for specific binding by
ELISA on diverse aggregates of Aβ42, corresponding to
the panning.Enzyme linked immunosorbent assay (ELISA)
Two kinds of ELISA (screening ELISA, antigen titration
ELISA) were performed as described before [74]. In both
cases a total of 100 ng of antigen per cavity was coated
in 96well MTPs (High Binding, Costar) at 4°C overnight.
All following steps were carried out at room temperature
on a rocker. For screening, scFvs were detected by mAb
9E10, recognizing the c-myc tag and a goat anti-mouse
antibody conjugated to horseradish peroxidase (Sigma
A0168). For titration, scFvs were detected by a mouse anti
penta-His (34660, Qiagen), recognizing the His tag and a
goat anti-mouse antibody conjugated to horseradish per-
oxidase (A0168, Sigma Aldrich). Bound scFv-Fc antibodies
were detected using a peroxidase-labeled goat anti-human
antibody recognizing the Fc fragment (A0170, Sigma-
Aldrich).ScFv and scFv-Fc antibody production and purification
The scFv inserts of positive clones were subcloned into
the pCSE2.5-HIS-XP and the pCSE2.5-hIgG1-Fc-XP vec-
tor, and the resulting scFv or scFv-Fc antibodies (Yumabs)
were transiently produced in HEK293-6E cells [75] as
described previously [45]. The cultivation medium was chem-
ically defined F17 medium (Invitrogen, Life Technologies)
supplemented with 7.5 mM L-glutamine, 0.1% PF68
(Applichem) and 1% Penicillin/Streptomycine. Antibody
fragments were purified using immobilized metal ion (Ni2+)
or protein A affinity chromatography on the Profinia™
Affinity Chromatography Protein Purification System
(BioRad), according to the manufacturer’s protocol.
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To assess the state of fibrillogenesis by Thioflavin T
(ThT) measurement, 20 μL of sample was mixed with
10 μL of ThT (100 μM) and 70 μL of glycine NaOH,
pH 8.5 (500 mM) in a well of a black 384-well Nunc plate
(Sigma-Aldrich). Fluorescence was measured in tripli-
cates on an Analyst™ AD fluorometer (Molecular Devices
Cooperation) at an excitation wavelength of λ = 450 nm
and emission wavelength of λ = 485 nm.
Epitope mapping
The peptide sequence of Aβ42 was divided into overlap-
ping peptide fragments of 15 aa length with an offset of
1 aa. The N-terminus was acetylated and two additional
glycines were added to the sequence to allow for proper
binding of the antibodies to the aspartic acid, the first aa of
Aβ42. The peptides were synthesized by the SPOT tech-
nique [76,77] and covalently bound to a continuous cellu-
lose membrane via their carboxy-terminus (JPT Peptide
Technologies GmbH). After initial incubation for 5 min in
methanol to prevent the precipitation of hydrophobic pep-
tides the membrane was rinsed with 1xTBS (50 mM TRIS,
137 mM NaCl, 2.7 mM KCl, pH adjusted to 8.0 with HCl)
and blocked in 2% (w/v) skim milk powder in 1xTBS (2%
M-TBS) for 1 h at room temperature on a rocker. ScFv-Fc
antibodies (10 μg/mL in 2% M-TBS) were incubated on
the membranes for 1.5 h at room temperature. Bound anti-
bodies were detected by using a peroxidase-labeled goat
anti-human antibody recognizing the Fc fragment (A0170,
Sigma-Aldrich). Development with SuperSignal West
Pico Chemiluminescent Substrate (Thermo Scientific)
according to manufacturer’s protocol on a ChemiDoc™
MP system (BioRad).
Affinity measurement
Antibody affinities were analyzed by surface plasmon res-
onance (SPR) using a BIAcore2000™. Aβ42 monomers and
protofibrils were immobilized on separate CM5 chips
(General Electric-Biacore), fibrils were immobilized on a
CMD50m chip (Xantec) via amine coupling according to
the manufacturers protocols. ScFvs were diluted to 100
nM - 10,000 nM (additionally to 15,000 nM for PaD97-D6
and 15,000 nM+ 20,000 nM for PaD213-A5) and added
to the chips in HBS-EP buffer according to the manufac-
turer’s protocol at a flow rate of 25 μL/min. Timeframes
were 200 s for association and 600 s for dissociation. After
each dilution, the chip was regenerated with NaOH ac-
cording to the manufacturer’s protocol. Data fitting was
performed using the “1:1 binding with drifting baseline”
algorithm of the BIAevaluation™ software.
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